Media stories about Editas Medicine (NASDAQ:EDIT) have trended somewhat positive on Monday, according to Accern. The research group identifies positive and negative media coverage by reviewing more than 20 million blog and news sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Editas Medicine earned a coverage optimism score of 0.03 on Accern’s scale. Accern also gave media headlines about the company an impact score of 44.1493831234839 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the immediate future.
A number of equities analysts recently commented on EDIT shares. Zacks Investment Research downgraded Editas Medicine from a “hold” rating to a “sell” rating in a research report on Tuesday, October 10th. Cann reaffirmed a “hold” rating on shares of Editas Medicine in a research report on Tuesday, November 7th. Morgan Stanley reissued an “equal weight” rating and set a $28.00 price objective (up from $27.00) on shares of Editas Medicine in a report on Friday, October 6th. Cowen reissued a “buy” rating on shares of Editas Medicine in a report on Tuesday, November 7th. Finally, BidaskClub lowered shares of Editas Medicine from a “buy” rating to a “hold” rating in a report on Thursday, December 7th. Two analysts have rated the stock with a sell rating, five have given a hold rating, five have issued a buy rating and one has given a strong buy rating to the stock. Editas Medicine has an average rating of “Hold” and an average target price of $26.73.
Editas Medicine (NASDAQ:EDIT) opened at $30.40 on Monday. Editas Medicine has a 1 year low of $13.12 and a 1 year high of $36.00. The company has a debt-to-equity ratio of 0.19, a quick ratio of 10.12 and a current ratio of 10.12. The firm has a market cap of $1,366.20, a PE ratio of -9.38 and a beta of 4.94.
Editas Medicine (NASDAQ:EDIT) last released its quarterly earnings results on Tuesday, November 7th. The company reported ($0.64) earnings per share for the quarter, missing the consensus estimate of ($0.60) by ($0.04). The company had revenue of $6.28 million for the quarter, compared to analyst estimates of $2.66 million. Editas Medicine had a negative return on equity of 70.19% and a negative net margin of 1,127.03%. The firm’s revenue for the quarter was up 553.0% on a year-over-year basis. During the same quarter last year, the company earned ($0.59) EPS. analysts forecast that Editas Medicine will post -2.92 earnings per share for the current year.
In related news, CFO Andrew A. F. Hack sold 5,000 shares of the stock in a transaction that occurred on Monday, November 20th. The shares were sold at an average price of $25.35, for a total transaction of $126,750.00. Following the completion of the transaction, the chief financial officer now owns 5,000 shares of the company’s stock, valued at approximately $126,750. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Katrine Bosley sold 14,995 shares of the stock in a transaction that occurred on Wednesday, January 3rd. The stock was sold at an average price of $34.15, for a total transaction of $512,079.25. The disclosure for this sale can be found here. In the last quarter, insiders sold 61,310 shares of company stock valued at $1,689,449. 19.40% of the stock is owned by insiders.
TRADEMARK VIOLATION WARNING: “Editas Medicine (EDIT) Given Daily News Sentiment Rating of 0.03” was reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this article on another publication, it was illegally stolen and reposted in violation of US and international copyright and trademark law. The legal version of this article can be read at https://www.dispatchtribunal.com/2018/01/22/somewhat-favorable-media-coverage-somewhat-unlikely-to-impact-editas-medicine-edit-share-price.html.
Editas Medicine Company Profile
Editas Medicine, Inc is a genome editing company. It is engaged in treating patients with genetically defined diseases by correcting their disease-causing genes. It operates through developing and commercializing genome editing technology segment. It is developing a genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR) technology.
Receive News & Ratings for Editas Medicine Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Editas Medicine and related companies with MarketBeat.com's FREE daily email newsletter.